Pfizer’s anti-Covid pill, marketed under the name Paxlovid, “makes a difference” by limiting the number of hospitalizations and deaths, at a time when the United States is experiencing a new epidemic wave, welcomed a senior White House official on Wednesday. After a sluggish start due to difficult access for patients, the drug, taken orally for five days as soon as possible after the onset of symptoms, has been used four times more in the past month, said Dr. Ashish Jha, new health crisis coordinator at the White House.
“20,000 prescriptions for Paxlovid are filled every day,” he told a news conference. “I think that’s a big reason why, despite the sharp rise in infections, we haven’t seen a comparable rise in deaths. We’ve seen an increase in hospitalizations, but not as much as expected at this point. “, he said. The United States is currently registering about 95,000 new reported cases of Covid-19 per day — an underestimated number due to the expansion of rapid home tests, the results of which are not always reported to authorities.
“Very broad” eligibility criteria
“I think Paxlovid makes a very big difference,” hammered Dr. Jha, recalling that the eligibility criteria for receiving the drug were “very broad” (people at risk of developing severe cases). This antiviral treatment works by reducing the ability of the virus to replicate, thus curbing the disease. Some patients have observed that they fall ill again after the five days of treatment, and then find themselves again positive for Covid. But it is difficult to estimate the frequency of these cases, and these people do not fall seriously ill, noted Dr. Jha.
Clinical trials are being considered to test whether longer treatment is needed, said White House adviser Dr. Anthony Fauci.
Congress under pressure
The White House also renewed its call for Congress to vote an additional $22.5 billion in funding. These funds must in particular make it possible to buy doses of vaccines with potentially updated formulas, to better combat the variants in circulation. Pharmaceutical companies are currently working on this possibility, and experts from the American Medicines Agency (FDA) are due to meet in June to discuss it.
“Without this additional congressional funding, we will not be able to purchase enough vaccines for all Americans who want one once these new generations of vaccines come out in the fall and winter,” warned Ashish Jha. “It would be terrible. We would see a lot of unnecessary deaths.”
According to him, other countries are already in discussion with the companies for these orders, which the United States cannot do for lack of means on the table. He said he “trusts” Congress to act, but is working on an alternative “plan”, potentially with access to new vaccines for those at risk only.